Michigan hospitals are systematically exploiting a program for low-income patients, according to a new report.

Following Eli Lilly and Johnson & Johnson, Sanofi is aiming to change how it participates in the 340B program, a federal drug pricing program created in 1992, The Wall Street Journal reported Nov. 22.

Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

The 340B Drug Discount Program was designed to help safety-net providers make drugs available to low-income patients and earn revenue. Drug manufacturers have put restrictions on which pharmacies ...

The 340B program is criticized for generating revenue rather than solely aiding underinsured patients, impacting community providers and Medicare patients. Pharmaceutical companies face challenges ...

WASHINGTON: The U.S. Department of Health and Human Services building is shown in Washington, DC. (Photo by Mark Wilson/Getty Images) In 1992, Congress created the 340B Drug Pricing Program to provide ...

The use of targeted therapy was similar between patients living in areas with the highest 340B penetration and patients living in areas with the lowest 340B penetration. Participation in the 340B Drug ...

Drug companies are at it again. They will not relent in their multiyear campaign to dismantle the 340B Drug Pricing Program. Drug companies are at it again. They will not relent in their multiyear ...